Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related
deaths in the US, despite only being the 11th most common cancer. The high mortality rates …

In this work, novel bioinspired polyurethane (PU) scaffolds were fabricated via freeze casting
for PU-based Pancreatic Ductal Adenocarcinoma (PDAC) model. In order to reproduce the …

In this manuscript, we elucidated, for the first time, the substructural mechanisms present in
our recently developed bioinspired polyurethane-based pancreatic tissue models. Different …

Beyond heterogeneous cancer cells, the tumor microenvironment includes stromal and
immune cells, blood vessels, extracellular matrix and biologically active molecules …

Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is currently the
fourth leading cause of cancer-related deaths and is predicted to become the second …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor. Prognosis is poor and
survival is low in patients diagnosed with this disease;~ 12% at 5 years. Immunotherapy …

Microarray technology has unlocked doors to a multitude of open analysis problems that if
conceived with efficacy may uncover varied genotypic and phenotypic traits. Algorithms …

Pancreatic ductal adenocarcinomas (PDACs) contribute to around 7% of all cancer-related
deaths worldwide with a 5-year survival rate less than 10%. The incidence of the disease is …

The field of immuno-oncology has gained great interest. Novel immune-enhancing treatment
modalities against cancer have been approved for some solid cancers, especially in …

Pancreatic adenocarcinoma is one of the most aggressive cancers and has a rising
incidence and high mortality. The high mortality rate is attributed to a lack of adequate …